Acute ischemic stroke (AIS) refers to an obstruction of blood flow to the brain caused by a blood clot or thrombus within a blood vessel leading to the brain. AIS is a medical emergency and timely treatment is crucial in minimizing brain damage. The major treatment options for AIS include thrombolytic drugs, mechanical thrombectomy devices, neurothrombectomy devices, and stenting devices. Thrombolytic drugs such as alteplase are the most commonly used treatment which helps dissolve blood clots. Mechanical thrombectomy devices are retrieval devices used to remove the clot mechanically from blocked arteries.

The global AIS therapeutics market is estimated to be valued at US$ 6.54 Bn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics
The increasing prevalence of strokes across the world is the primary driver propelling the growth of the AIS therapeutics market. As per estimates, every year, over 800,000 people in the US suffer a new or recurrent stroke. Similarly, globally over 100 million people are affected by strokes. The rising prevalence of key risk factors such as hypertension, diabetes, obesity, atherosclerosis, heart diseases, and smoking are contributing to the increasing incidence of strokes worldwide. The second driver augmenting the market growth is the ongoing development and approval of novel drugs and devices. In recent years, many novel mechanical thrombectomy devices and stenting devices have received regulatory approvals which are improving treatment outcomes for AIS patients. However, the high costs associated with AIS treatment options such as thrombectomy devices are limiting market growth.

SWOT Analysis

Strength: Acute ischemic stroke is one of the leading causes of disability and the fifth leading cause of death in the United States. Early diagnosis and treatment can help minimize long-term effects. Advances in treatments such as thrombolysis and thrombectomy have improved outcomes.

Weakness: Access to advanced stroke care remains limited, especially in rural areas. Many ambulances are not equipped for rapid transport to comprehensive stroke centers. Older patients may not recognize or report symptoms in time for treatment.

Opportunity: Growing elderly population is increasing the risk of AIS. Social awareness campaigns can help the public recognize signs of stroke and call for emergency help. Expanding telestroke networks may help link rural hospitals to specialist care.

Threats: Risk factors for stroke such as diabetes, obesity and lack of physical activity are on the rise. This could drive greater disease incidence in coming years. Rising healthcare costs may limit access to new, expensive stroke therapies.

Key Takeaways

The global Acute ischemic stroke (AIS) market size is expected to witness high growth over the forecast period of 2023 to 2030 supported by rising geriatric population and increasing awareness. The global AIS therapeutics market is estimated to be valued at US$ 6.54 Bn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030.

The North American region holds the largest share of the global AIS market due to presence of advanced healthcare facilities and growing elderly population susceptible to strokes. The United States faces high costs of stroke management prompting ongoing research into preventive strategies. Europe is the second largest market with heavy funding support for stroke innovation from research councils.

Key players: Key players operating in the acute ischemic stroke market are Medtronic, Stryker, Johnson & Johnson, Abbott Vascular, Boston Scientific, and Teleflex Incorporated. These companies offer a range of devices for minimally invasive thrombectomy procedures to restore blood flow in blocked arteries and dissolved clots using thrombolytic drugs.

Get more insights on this topic: https://www.newswirestats.com/acute-ischemic-stroke-ais-market-size-and-outlook-2023-2030/